Accessibility: Skip TopNav
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease
Format
JPEG
Source
Biogen Inc.
Downloads
Original
Large
Medium
Small